+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Summit Therapeutics plc - logo

Summit Therapeutics is a biopharmaceutical company focussed on the development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

From
From
Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024 - Product Thumbnail Image

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 70 Pages
  • Global
From
From
From
2021 Clinical Trial Analytics of the Microbiome Landscape - Product Thumbnail Image

2021 Clinical Trial Analytics of the Microbiome Landscape

  • Report
  • April 2021
  • 9 Pages
  • Global
Global Clostridium Difficile Treatment Market 2021-2025 - Product Thumbnail Image

Global Clostridium Difficile Treatment Market 2021-2025

  • Report
  • July 2021
  • 120 Pages
  • Global
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • March 2024
  • 1000 Pages
  • Global
From
From
Klebsiella pneumoniae Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Klebsiella pneumoniae Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 140 Pages
  • Global
From
Acinetobacter Infections - Pipeline Review, H2 2020 - Product Thumbnail Image

Acinetobacter Infections - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 204 Pages
  • Global
From
Loading Indicator